miR-330-5p靶向调控OY-TES-1抑制胶质母细胞瘤的迁移

梁国; 赵振凯; 曾曌月; 张庆梅; 农蔚霞; 谢小薰; 李希圣

doi:10.11659/jjssx.03E024085

您当前的位置：

首页 >

文章列表页 >

miR-330-5p靶向调控OY-TES-1抑制胶质母细胞瘤的迁移

基础研究 | 更新时间：2025-01-21

- miR-330-5p靶向调控OY-TES-1抑制胶质母细胞瘤的迁移
- MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma
- 局解手术学杂志 2025年34卷第2期页码：98-103
- 作者机构：
  
  1.广西医科大学基础医学院组织学与胚胎学教研室，广西南宁 530021
  2.广西医学科学院·广西壮族自治区人民医院颅脑肿瘤创伤功能神经外科，广西南宁 530021
- 作者简介：
  
  谢小薰，E-mail：xiaoxunxie59@foxmail.com
  李希圣，E-mail：lxssky@hotmail.com
- 基金信息：
  
  南宁市青秀区科技计划项目(2019037)
- DOI：10.11659/jjssx.03E024085
  中图分类号： R392.12
- 纸质出版日期：2025-02-25，
  
  收稿日期：2024-03-16，
- 稿件说明：
移动端阅览
梁国, 赵振凯, 曾曌月, 等. miR-330-5p靶向调控OY-TES-1抑制胶质母细胞瘤的迁移[J]. 局解手术学杂志, 2025,34(2):98-103.

LIANG GUO, ZHAO ZHEN-KAI, ZENG ZHAO-YUE, et al. MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma. [J]. Journal of regional anatomy and operative surgery, 2025, 34(2): 98-103.
梁国, 赵振凯, 曾曌月, 等. miR-330-5p靶向调控OY-TES-1抑制胶质母细胞瘤的迁移[J]. 局解手术学杂志, 2025,34(2):98-103. DOI： 10.11659/jjssx.03E024085.

LIANG GUO, ZHAO ZHEN-KAI, ZENG ZHAO-YUE, et al. MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma. [J]. Journal of regional anatomy and operative surgery, 2025, 34(2): 98-103. DOI： 10.11659/jjssx.03E024085.

摘要

目的

探究胶质母细胞瘤中miR-330-5p对OY-TES-1的靶向调控关系以及miR-330-5p/OY-TES-1轴对胶质母细胞瘤的迁移能力的影响。

方法

生物信息学分析胶质母细胞瘤患者中miR-330-5p的表达水平及其对患者预后生存的影响。将胶质母细胞瘤细胞U251分为miR-330-5p minics组、minics-NC组和miR-330-5p+OY-TES-1过表达组（miR-330-5p minics+pcDNA3.1-OY-TES-1）。使用双荧光素酶报告基因实验检测miR-330-5p对OY-TES-1 3'UTR区域活性的影响；使用qRT-PCR检测OY-TES-1 mRNA表达；采用Transwell迁移实验检测miR-330-5p/OY-TES-1轴对胶质母细胞瘤细胞迁移能力的影响。

结果

胶质母细胞瘤组织中miR-330-5p的表达明显低于非瘤脑组织和低级别胶质瘤组织(

0.05)。高表达miR-330-5p的胶质母细胞瘤患者生存期显著长于低表达miR-330-5p患者(

0.05)。过表达miR-330-5p后OY-TES-1 3'UTR区域活性下降

0.05)。与minics-NC组相比，miR-330-5p minics组U251和U87MG细胞中OY-TES-1 mRNA表达水平显著降低(

0.01)。与minics-NC组相比，miR-330-5p minics组及miR-330-5p+OY-TES-1过表达组迁移细胞数显著减少（

0.05）；与miR-330-5p minics组相比，miR-330-5p+OY-TES-1过表达组迁移细胞数显著增加（

0.01）。

结论

miR-330-5p靶向调控OY-TES-1抑制胶质母细胞瘤的迁移。

Abstract

Objective

To explore the targeted regulatory relationship of miR-330-5p on OY-TES-1 in glioblastoma and the effect of miR-330-5p/OY-TES-1 axis on the migration ability of glioblastoma.

Methods

Bioinformatics analysis was performed to analyze the expression level of miR-330-5p in patients with glioblastoma and its influence on prognosis and survival of patients. The glioblastoma cells U251 were divided into miR-330-5p minics group， minics-NC group， and miR-330-5p+OY-TES-1 overexpression group （miR-330-5p minics+pcDNA3.1-OY-TES-1）. The effect of miR-330-5p on the activity of OY-TES-1 3'UTR region was detected by double luciferase reporter gene experiment. The expression of OY-TES-1 mRNA was detected by qRT-PCR. The effect of miR-330-5p/OY-TES-1 axis on the migration ability of glioblastoma cells was detected by Transwell migration assay.

Results

The expression of miR-330-5p in glioblastoma tissue was significant

ly lower than those in non-tumor brain tissue and low-grade glioma tissue （

0.05）. The survival time of glioblastoma patients with high expression of miR-330-5p was significantly longer than that of patients with low expression of miR-330-5p （

0.05）. After overexpression of miR-330-5p， the activity of OY-TES-1 3'UTR region was decreased （

0.05）. Compared with minics-NC group， the expression levels of OY-TES-1 mRNA of U251 and U87MG cells in miR-330-5p minics group were significantly decreased （

0.01）. Compared with minics-NC group， the numbers of migrating cells in miR-330-5p minics group and miR-330-5p+OY-TES-1 overexpression group were significantly decreased （

0.05）. Compared with miR-330-5p minics group， the number of migrating cells in miR-330-5p+OY-TES-1 overexpression group was significantly increased （

0.01）.

Conclusion

MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma.

关键词

miR-330-5pOY-TES-1胶质母细胞瘤细胞迁移

Keywords

miR-330-5pOY-TES-1glioblastomacell migration

references

Kohler BA，Ward E，McCarthy BJ，et al.Annual report to the nation on the status of cancer，1975-2007，featuring tumors of the brain and other nervous system［J］.J Natl Cancer Inst，2011，103（9）：714-736.doi：10.1093/jnci/djr077http://dx.doi.org/10.1093/jnci/djr077.

Ostrom QT，Gittleman H，Truitt G，et al.CBTRUS statistical report：primary brain and other central nervous system tumors diagnosed in the united states in 2011-2015［J］.Neuro Oncol，2018，20（suppl_4）：iv1-iv86.doi：10.1093/neuonc/noy131http://dx.doi.org/10.1093/neuonc/noy131.

Julka PK，Sharma DN，Mallick S，et al.Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide ：a mono-institutional experience of 215 patients［J］.J Cancer Res Ther，2013，9（3）：381-386.doi：10.4103/0973-1482.119310http://dx.doi.org/10.4103/0973-1482.119310.

Morgan LL.The epidemiology of glioma in adults：a "state of the science" review［J］.Neuro Oncol，2015，17（4）：623-624.doi：10.1093/neuonc/nou358http://dx.doi.org/10.1093/neuonc/nou358.

Dai L，Liang W，Shi Z，et al.Systematic characterization and biological functions of non-coding RNAs in glioblastoma［J］.Cell Prolif，2023，56（3）：e13375.doi：10.1111/cpr.13375http://dx.doi.org/10.1111/cpr.13375.

Li Y，Xu J，Chen H，et al.Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression［J］.Nucleic Acids Res，2013，41（22）：e203.doi：10.1093/nar/gkt1054http://dx.doi.org/10.1093/nar/gkt1054.

Sumazin P，Yang X，Chiu HS，et al.An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma［J］.Cell，2011，147（2）：370-381.doi：10.1016/j.cell.2011.09.041http://dx.doi.org/10.1016/j.cell.2011.09.041.

Yan C，Kong X，Gong S，et al.Recent advances of the regulation roles of MicroRNA in glioblastoma［J］.Int J Clin Oncol，2020，25（7）：1215-1222.doi：10.1007/s10147-020-01685-yhttp://dx.doi.org/10.1007/s10147-020-01685-y.

Yoo HI，Kim BK，Yoon SK.MicroRNA-330-5p negatively regulates ITGA5 expression in human colorectal cancer［J］.Oncol Rep，2016，36（5）：3023-3029.doi：10.3892/or.2016.5092http://dx.doi.org/10.3892/or.2016.5092.

Tréhoux S，Lahdaoui F，Delpu Y，et al.Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells［J］.Biochim Biophys Acta，2015，1853（10 Pt A）：2392-2403.doi：10.1016/j.bbamcr.2015.05.033http://dx.doi.org/10.1016/j.bbamcr.2015.05.033.

Tammela J，Uenaka A，Ono T，et al.OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer［J］.Int J Oncol，2006，29（4）：903-910.

Fan R，Huang W，Luo B，et al.Cancer testis antigen OY-TES-1：analysis of protein expression in ovarian cancer with tissue microarrays［J］.Eur J Gynaecol Oncol，2015，36（3）：298-303.

Li X，Yan J，Fan R，et al.Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma［J］.Oncol Lett，2017，13（5）：3080-3086.doi：10.3892/ol.2017.5799http://dx.doi.org/10.3892/ol.2017.5799.

Luo B，Yun X，Fan R，et al.Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer：its relationship to clinicopathological parameters［J］.Int J Clin Exp Pathol，2013，6（12）：2835-2845.

范蓉，肖绍文，黄巍，等.肝细胞癌中OY-TES-1基因mRNA的表达［J］.肿瘤防治研究，2010，37（7）：810-812.doi：10.3971/j.issn. 1000-8578.2010.07.020http://dx.doi.org/10.3971/j.issn.1000-8578.2010.07.020.

Pierscianek D，Ahmadipour Y，Oppong MD，et al.Blood-based biomarkers in high grade gliomas：a systematic review［J］.Mol Neurobiol，2019，56（9）：6071-6079.doi：10.1007/s12035-019-1509-2http://dx.doi.org/10.1007/s12035-019-1509-2.

Young JS，Dayani F，Morshed RA，et al.Immunotherapy for high-grade gliomas：a clinical update and practical considerations for neurosurgeons［J］.World Neurosurg，2019，124：397-409.doi：10.1016/j.wneu.2018.12.222http://dx.doi.org/10.1016/j.wneu.2018.12.222.

Dehaini H，Awada H，El-Yazbi A，et al.MicroRNAs as potential pharmaco-targets in ischemia-reperfusion injury compounded by diabetes［J］.Cells，2019，8（2）：152.doi：10.3390/cells8020152http://dx.doi.org/10.3390/cells8020152.

Si W，Shen J，Zheng H，et al.The role and mechanisms of action of microRNAs in cancer drug resistance［J］.Clin Epigenetics，2019，11（1）：25.doi：10.1186/s13148-018-0587-8http://dx.doi.org/10.1186/s13148-018-0587-8.

Chen R，Wang G，Zheng Y，et al.Drug resistance-related microRNAs in osteosarcoma：translating basic evidence into therapeutic strategies［J］.J Cell Mol Med，2019，23（4）：2280-2292.doi：10.1111/jcmm. 14064http://dx.doi.org/10.1111/jcmm.14064.

Qi Y，Wang X，Kong X，et al.Expression signatures and roles of microRNAs in inflammatory breast cancer［J］.Cancer Cell Int，2019，19：23.doi：10.1186/s12935-018-0709-6http://dx.doi.org/10.1186/s12935-018-0709-6.

Sun G，Cao Y，Shi L，et al.Overexpressed miRNA-137 inhibits human glioma cells growth by targeting Rac1［J］.Cancer Biother Radiopharm，2013，28（4）：327-334.doi：10.1089/cbr.2012.1380http://dx.doi.org/10.1089/cbr.2012.1380.

Cavallo F，De Giovanni C，Nanni P，et al.2011：the immune hallmarks of cancer［J］.Cancer Immunol Immunother，2011，60（3）：319-326.doi：10.1007/s00262-010-0968-0http://dx.doi.org/10.1007/s00262-010-0968-0.

Pang Y， Young CY， Yuan H. MicroRNAs and prostate cancer［J］. Acta Biochim Biophys Sin （Shanghai），2010，42（6）：363-369. doi：10.1093/abbs/gmq038http://dx.doi.org/10.1093/abbs/gmq038.

Wang MH，Liu ZH，Zhang HX，et al.Hsa_circRNA_000166 accelerates breast cancer progression via the regulation of the miR-326/ELK1 and miR-330-5p/ELK1 axes［J］.Ann Med，2024，56（1）：2424515.doi：10.1080/07853890.2024.2424515http://dx.doi.org/10.1080/07853890.2024.2424515.

Chen L，Yang X，Zhao J，et al.Circ_0008532 promotes bladder cancer progression by regulation of the miR-155-5p/miR-330-5p/MTGR1 axis［J］.J Exp Clin Cancer Res，2020，39（1）：94.doi：10.1186/s13046-020-01592-0http://dx.doi.org/10.1186/s13046-020-01592-0.

Xu S，Lei SL，Liu KJ，et al.circSFMBT1 promotes pancreatic cancer growth and metastasis via targeting miR-330-5p/PAK1 axis［J］.Cancer Gene Ther，2021，28（3-4）：234-249.doi：10.1038/s41417-020-00215-2http://dx.doi.org/10.1038/s41417-020-00215-2.

Cheng H，Wang N，Tian J，et al.Circular RNA Circ_0025033 promotes the evolvement of ovarian cancer through the regulation of miR-330-5p/KLK4 Axis［J］.Cancer Manag Res，2020，12：2753-2765.doi：10.2147/cmar.S241372http://dx.doi.org/10.2147/cmar.S241372.

Scanlan MJ，Gure AO，Jungbluth AA，et al.Cancer/testis antigens：an expanding family of targets for cancer immunotherapy［J］.Immunol Rev，2002，188：22-32.doi：10.1034/j.1600-065x.2002.18803.xhttp://dx.doi.org/10.1034/j.1600-065x.2002.18803.x.

Saproo S，Sarkar SS，Gupta E，et al.MiR-330-5p and miR-1270 target essential components of RNA polymerase I transcription and exhibit a novel tumor suppressor role in lung adenocarcinoma［J］.Cancer Gene Ther，2023，30（2）：288-301.doi：10.1038/s41417-022-00544-4http://dx.doi.org/10.1038/s41417-022-00544-4.

Liu J，Yue K，Yang J，et al.miR-330-5p suppress cell growth and invasion via disrupting HSF4-mediated MACC1/STAT3 pathway in colorectal cancer［J］.Front Biosci （Landmark Ed），2024，29（2）：53.doi：10.31083/j.fbl2902053http://dx.doi.org/10.31083/j.fbl2902053.

Kim BK，Yoo HI，Choi K，et al.miR-330-5p inhibits proliferation and migration of keratinocytes by targeting Pdia3 expression［J］.FEBS J，2015，282（24）：4692-4702.doi：10.1111/febs.13523http://dx.doi.org/10.1111/febs.13523.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

迷迭香酸通过PI3K/AKT/mTOR信号通路抑制喉癌细胞的增殖和迁移

大豆苷元靶向MMP12发挥抗口腔鳞状细胞癌的作用

miR-483靶向调控DLC1对三阴性乳腺癌细胞增殖、迁移和侵袭的影响